The importance of glucose‐dependent insulinotropic polypeptide receptor activation for the effects of tirzepatide
The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
Tirzepatide is a unimolecular co‐agonist of the glucagon‐like peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP) receptors recently approved for the treatment of type 2 diabetes by the US Food and Drug Administration and the European Medicine Agency. Tirzepatide treatment results in an unprecedented improvement of glycaemic control and lowering of body weight, but the contribution of the GIP receptor‐activating component of tirzepatide to these effects is uncertain. In this review, we present the current knowledge about the physiological roles of the incretin hormones GLP‐1 and GIP, their receptors, and previous results of co‐targeting the two incretin hormone receptors in humans. We also analyse the molecular pharmacological, preclinical and clinical effects of tirzepatide to discuss the role of GIP receptor activation for the clinical effects of tirzepatide. Based on the available literature on the combination of GLP‐1 and GIP receptor activation, tirzepatide does not seem to have a classical co‐activating mode of action in humans. Rather, in vitro studies of the human GLP‐1 and GIP receptors reveal a biased GLP‐1 receptor activation profile and GIP receptor downregulation. Therefore, we propose three hypotheses for the mode of action of tirzepatide, which can be addressed in future, elaborate clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 2×
“For all phase 2 17,18 and phase 3 studies of tirzepatide, 19 – 26 reported adverse events have been dominated by mild to moderate, transient, dose-dependent gastrointestinal effects (nausea, diarrhoea and vomiting), very similar to those observed during treatment with GLP-1 receptor agonists.”
BackgroundResultFredriksson, R., Lagerström, M. C., Lundin, L.-G., & Schiöth, H. B. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.6.1256 · Cited by 2,941
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
A Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039 · cited 1×
“13 GLP-1 receptor agonist treatment results in an increase in heart rate by a few beats per minute with some variation throughout the day, presumably because of direct activation of cardiovascular GLP-1 receptors.”
BackgroundNauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Self-citationGLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647 · cited 2×
“71 A 6-week continuous GLP-1 infusion improved insulin sensitivity compared with placebo, but the improvement was probably attributable to the concomitant weight loss.”
BackgroundSelf-citationSattar, N., Lee, M. M. Y., Kristensen, S. L., Branch, K. R. H., Del Prato, S., Khurmi, N. S., Lam, C. S. P., Lopes, R. D., McMurray, J. J. V., Pratley, R. E., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00203-5 · Cited by 1,599 · cited 3×
“11 Because of potential beneficial effects (such as anti-inflammation) of GLP-1 receptor agonism in several organs including the central nervous system, novel indications (e.g. Alzheimer's disease, 12 non-alcoholic fatty liver disease, 13 heart failure with preserved ejection fraction 14 and bile…”
BackgroundInfluential9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s009 · Cited by 1,555
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · cited 1×
“72 For GIP, the insulino-tropic effect is severely reduced in patients with type 2 diabetes, 73 – 75 but to a limited extent restorable by normalization of plasma glucose (2-4 weeks).”
BackgroundSelf-citationNauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092 · cited 2×
“4 However, the insulinotropic effect of intravenous GIP infusions was found to be severely reduced or even absent in patients with type 2 diabetes, 4 – 6 in whom GIP also turned out to stimulate glucagon secretion and impair postprandial glucose tolerance.”
BackgroundSelf-citation
Research works printed but not linked: 70
- 10.1016/S0140-6736(87)91194-9 · DOI · Paper page
- 10.1210/jc.2003-030738 · DOI · Paper page
- 10.2337/db08-0958 · DOI · Paper page
- 10.1186/s13063-019-3259-x · DOI · Paper page
- 10.1007/s10741-021-10106-9 · DOI
- 10.1016/S2468-1253(22)00198-4 · DOI
- 10.1016/S0140-6736(21)01324-6 · DOI · Paper page
- 10.1016/S0140-6736(21)02188-7 · DOI · Paper page
- 10.1007/s00125-017-4450-9 · DOI · Paper page
- 10.1210/jc.76.4.912 · DOI · Paper page
- 10.1016/0167-0115(94)90136-8 · DOI · Paper page
- 10.1111/j.1365-2265.2008.03451.x · DOI · Paper page
- 10.1152/ajpendo.00665.2010 · DOI · Paper page
- 10.1152/ajpgi.1998.275.5.G984 · DOI · Paper page
- 10.14814/phy2.13102 · DOI
- 10.1210/jc.2013-3766 · DOI · Paper page
- 10.3389/fcell.2021.749607 · DOI · Paper page
- 10.1016/j.bone.2020.115553 · DOI
- 10.1002/jbmr.4308 · DOI
- 10.1530/EC-17-0015 · DOI · Paper page
- 10.2337/db11-1451 · DOI · Paper page
- 10.1016/j.peptides.2019.170224 · DOI · Paper page
- 10.1016/j.peptides.2022.170749 · DOI · Paper page
- 10.1016/j.bcp.2020.114001 · DOI · Paper page
- 10.1016/j.bcp.2018.01.040 · DOI
- 10.1074/jbc.M213179200 · DOI
- 10.1128/MCB.00256-14 · DOI · Paper page
- 10.1111/bph.13323 · DOI · Paper page
- 10.1016/j.cmet.2017.11.003 · DOI
- 10.2337/db21-0848 · DOI · Paper page
- Bergmann NC, 2022, Diabetes, Obesity and Metabolism, 18
- 10.1007/s00125-021-05547-8 · DOI
- 10.1210/clinem/dgac542 · DOI
- NovoNordisk, 2023, Financial Report for 1 January 2023 to 31 March 2023, 1
- 10.2337/db13-1455 · DOI · Paper page
- Stensen S, 2022, Endogenous glucose‐dependent insulinotropic polypeptide contributes to sitagliptin‐mediated improvement in β‐cell function in patients with type 2 diabetes, Diabetes, 71, 2209
- Nauck MA, 1993, Preserved incretin activity of glucagon‐like peptide 1 [7‐36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type‐2 diabetes mellitus, JClinInvest, 91, 301
- 10.2337/diabetes.50.11.2497 · DOI · Paper page
- Hoe B, 2022, Improved glycemic control in patients with type 2 diabetes improves beta cell actions of endogenous glucose‐dependent insulinotropic polypeptide, Diabetes, 71, 1
- Adriaenssens AE, 2020, The glucose‐dependent insulinotropic polypeptide signaling axis in the central nervous system, Peptides, 125, 170
- 10.2337/db13-1627 · DOI · Paper page
- 10.1530/EJE-21-0135 · DOI · Paper page
- 10.1210/jc.2015-3133 · DOI · Paper page
- 10.1016/j.beem.2004.08.007 · DOI
- 10.1111/jgh.13026 · DOI · Paper page
- Kanie T, 2021, Dipeptidyl peptidase‐4 inhibitors, glucagon‐like peptide 1 receptor agonists and sodium‐glucose co‐transporter‐2 inhibitors for people with cardiovascular disease: a network meta‐analysis, Cochrane Database Syst Rev, 10, 1
- 10.2337/db12-0976 · DOI · Paper page
- 10.1161/HYPERTENSIONAHA.121.17852 · DOI
- 10.1016/j.peptides.2017.12.021 · DOI · Paper page
- Gabe MBN, 2022, GIP and GLP‐2 together improve bone turnover in humans supporting GIPR‐GLP‐2R co‐agonists as future osteoporosis treatment, Pharmacol Res, 176, 1
- EMEA/H/C/005620/0000, 2022, Assessment Report
- 10.2337/db23-127-OR · DOI
- 10.1038/s41401-021-00758-6 · DOI
- Zhao F, 2021, Structural insights into hormone recognition by the human glucose‐dependent insulinotropic polypeptide receptor, Elife, 10, 1
- 10.1073/pnas.2116506119 · DOI · Paper page
- 10.1111/dom.14572 · DOI · Paper page
- 10.1007/s40262-022-01140-3 · DOI · Paper page
- 10.1038/s41467-018-03941-2 · DOI · Paper page
- 10.1172/JCI140046 · DOI · Paper page
- 10.1172/JCI143199 · DOI
- 10.1210/jc.2004-2460 · DOI · Paper page
- 10.3389/fendo.2020.00178 · DOI · Paper page
- 10.1111/dom.13018 · DOI · Paper page
- Amgen, 2022, AMG 133 is a first‐in‐class investigational bispecific molecule that activates GLP‐1R and inhibits GIPR
- 10.1016/j.coph.2020.08.011 · DOI
- 10.1111/bph.13384 · DOI · Paper page
- 10.1111/dom.14736 · DOI
- 10.1017/S0007114511005228 · DOI
- 10.1016/j.mce.2014.10.025 · DOI
- 10.1210/jc.2019-00008 · DOI · Paper page
Cited by
What is the pipeline for future medications for obesity?
Melson, E., Ashraf, U., Papamargaritis, D., & Davies, M. J. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01473-y · Cited by 332
“Nevertheless, a number of other hypotheses have been suggested and both GIP receptor activation and GIP receptor antagonism have been proposed as potential mechanisms to tirzepatide ’ s ef fi cacy [53].”
GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management
Holst, J. J. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01113-9 · Cited by 125
“The effectiveness of tirzepatide with respect to both its antidiabetic and its anti-obesity actions is impressive and indisputable but contrasts with expectations regarding the contribution of GIP activity to the effects of the co-agonist 166 .”
Self-citationApperloo, E. M., Tuttle, K. R., Pavo, I., Haupt, A., Taylor, R., Wiese, R. J., Hemmingway, A., Cherney, D. Z. I., Sattar, N., & Heerspink, H. J. L. (2025) · Diabetes Care · doi:10.2337/dc24-1773 · Cited by 53
Madsbad, S., & Holst, J. J. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2472408 · Cited by 43
“The binding to the GIP receptor is comparable to that of native GIP, while the binding affinity for the GLP-1 receptor is five times lower than that of the native hormone [69].”
Self-citationHoffmann, K., Michalak, M., Rizzo, M., Maggio, V., & Paczkowska, A. (2026) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2586703 · Cited by 8
“Tirzepatide (Ly3298176) engages both glucose-dependent insu-linotropic polypeptide receptor (GIPR) and GLP-1 receptor (GLP-1 R) simultaneously (dual agonism), enhancing insulin secretion, reducing glucagon levels, and promoting appetite suppression and weight loss [8–11].”
Metadata
- Authors
- Gasbjerg, L. S., Rosenkilde, M. M., Meier, J. J., Holst, J. J., & Knop, F. K.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2023-08-08
- Volume
- 25
- Issue
- 11
- Pages
- 3079-3092
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W4385663314
- Cited by
- 41
- References
- 62
- FWCI
- 6.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.